Cell therapy developer NeoStem has agreed to acquire California Stem Cell in a deal worth up to $124M, and includes CSC’s manufacturing facility in Irvine, CA.
Thermo Fisher has launched a pump technology designed for applications across the bioprocessing production line and usable with "all" bioprocessing tech.
Catalent will provide Hisun Pharmaceuticals with cell lines to help it develop infliximab, adalimumab and alemtuzumab biosimilars for the Chinese market.
Development of new anti-choloesterol drugs containing proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibiting monoclonal antibodies could double Repligen Bioprocessing’s earning power, according to a Jefferies analyst.
The High Court in London has revoked two patents referring to the dosage and composition of Roche’s monoclonal antibody drug Herceptin, paving the way for Hospira’s biosimilar product.
As larger partnerships between CROs and sponsors come to maturity, a new survey found that “a much greater proportion of CRO revenue growth” will come from small and medium-sized pharma and biotech sponsor deals.
Pfizer has reminded the creator of Viagra-flavoured ice cream that the blockbuster erectile dysfunction treatment should only be available on prescription.
Novartis subsidiary Alcon has opened the doors to its new $160m facility in Singapore for the manufacture of ophthalmic drugs.
Acura has reacquired the rights to its opioid abuse-deterrent technology from Pfizer and is looking for pharma partners to relaunch its oxycodone HCL drug Oxecta.
US health insurer Independence Blue Cross (IBC) has selected LabCorp to be its preferred provider for outpatient and specialty lab services under a new eight year deal.
Hovione has obtained a US patent for a cheap capsule-based dry powder inhaler that it claims is cheaper for manufacturers to produce and easier for patients to use.
A recent study found that CRO employees are seeing rapid budget increases for salaries across the globe, with an average increase of about 4% for 2014.